He was found to have proteinuria and poor kidney function, and his kidney function was also very poor. Professor Wang Xiaobo, head of the subspecialty of myeloma in the Department of Hematology of the Second Affiliated Hospital of Dalian Medical University, concluded that the patient’s primary disease was not a kidney disease, but most likely a malignant tumor of the blood, multiple myeloma, causing kidney damage, after careful medical history, physical examination and review of past labs. The patient was clearly diagnosed with multiple myeloma and secondary renal insufficiency. So what kind of disease is multiple myeloma? This tumor starts in the bone marrow, so it belongs to the category of hematological diseases and is a common malignant tumor in hematology. The tumor cells can secrete excessive amounts of pathological immunoglobulins or light chains, causing obstruction of renal tubules, amyloidosis of the kidneys or hypercalcemia, resulting in kidney damage or even uremia, which is the case of Master Li. In addition, multiple myeloma also causes bone destruction, which mostly occurs in the lumbar vertebrae and ribs. Patients often have symptoms such as back pain and bone pain, while tumor cells destroy the human immune system and inhibit normal hematopoiesis, and patients are often prone to infection and anemia. The Department of Hematology of the Second Affiliated Hospital of Dalian Medical University has set up a special subspecialty of myeloma, and its head, Professor Wang Xiaobo, said that among the hundreds of myeloma patients treated in recent years, many of them came to the Department of Hematology only after taking many detours, because the clinical manifestations of myeloma patients are complex and diverse, involving many disciplines, and because some medical personnel are inexperienced, clinical misdiagnosis and omission occur from time to time. Many patients with myeloma often go to nephrology and orthopedics first, or take some so-called blood tonic drugs by themselves, and the disease process is insidious and often overlooked. Multiple myeloma is a common malignant tumor of the hematological system, which is more common in middle-aged and elderly people, accounting for about 10% of hematological malignant tumors. If you have back pain, bone pain, proteinuria, unexplained anemia, pathological fracture, abnormally elevated liver function globulin or significantly increased blood sedimentation, you should be alert to the occurrence of myeloma, and you should go to the hematology department in time to perform relevant examinations to make timely diagnosis, shorten the time from consultation to diagnosis, and reduce the financial burden of unnecessary examinations on patients. In the era of applying traditional chemotherapy regimens, the complete remission rate of myeloma is less than 10%, said Prof. Wang. In recent years, scholars at home and abroad have conducted many studies on myeloma. In recent years, with the emergence of some new drugs including thalidomide, bortezomib and ralidomide and the combination of new drugs, which bring good news to myeloma patients, the subspecialty of myeloma in the Department of Hematology of the Second Affiliated Hospital of Dalian Medical University combines the international standard diagnostic and treatment process of myeloma to provide individualized and standardized treatment for patients, especially for myeloma patients with a variety of serious complications combined with many successful treatment experiences. Nearly one-third of myeloma patients admitted to the Department of Hematology have kidney involvement, including some patients with renal failure reaching uremia. It is precisely by treating such patients with new treatment concepts such as targeted drugs that their tumors are controlled and their kidney function is improved, and some of them even get off hemodialysis.